Small Cap Stocks in Focus: ION, A8G, AAJ and NUZ Progress Separate Programmes

Aditi Sarkar

16 September 2026 01:57 PM AEST

Small Cap Stocks in Focus: ION, A8G, AAJ and NUZ Progress Separate Programmes

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Iondrive, Australasian Metals, Aruma Resources and Neurizon Therapeutics update 1: small-cap ASX stocks rarely move for the same reason twice, and that is true of this group.
Iondrive, Australasian Metals, Aruma Resources and Neurizon Therapeutics update 2: iondrive Limited (ASX:ION) has released updated Economics for a rare-earth recycling technology.
Iondrive, Australasian Metals, Aruma Resources and Neurizon Therapeutics update 3: australasian Metals Limited (ASX:A8G) has secured an option over lithium projects in West Africa.
Iondrive, Australasian Metals, Aruma Resources and Neurizon Therapeutics update 4: aruma Resources Limited (ASX:AAJ) has been drilling a copper-silver target in Canada.

Iondrive, Australasian Metals, Aruma Resources and Neurizon Therapeutics (ASX:ION, A8G, AAJ and NUZ) is moving four separate small-cap programmes through its current technical and corporate programme. For this specific update, the disclosed work separates completed activity from unverified outcomes and identifies the remaining decisions affecting four separate small-cap programmes.

Company Business

Small-cap ASX stocks rarely move for the same reason twice, and that is true of this group. Iondrive Limited (ASX:ION) has released updated economics for a rare-earth recycling technology. Australasian Metals Limited (ASX:A8G) has secured an option over lithium projects in West Africa. Aruma Resources Limited (ASX:AAJ) has been drilling a copper-silver target in Canada. And Neurizon Therapeutics Limited (ASX:NUZ) has taken a capital-management step while advancing a motor neurone disease drug candidate through a major US clinical trial. None of the four is currently confirmed as a member of a named S&P/ASX benchmark index.

Iondrive's core technology addresses a genuine supply-chain problem: the world's growing Volume of end-of-life batteries, magnets and electronic waste, and the difficulty of recovering critical minerals from it economically. The company operates two related processing routes - a deep eutectic solvent (DES) process aimed at Lithium-Ion Battery recycling, and a separate module called IONSolv, aimed at recovering heavy rare earth elements such as dysprosium, neodymium and praseodymium from permanent-magnet feedstock, including e-waste.

Current Programme

On 7 September 2026, Iondrive released updated project economics for a proposed IONSolv processing module in Oklahoma, United States. The study estimated a post-tax net present value of USA$243 million, annual EBITDA of USA$62.1 million and annual Revenue of USA$121.8 million, against development Capital of USA$11.9 million, based on processing around 2,402 tonnes of feedstock a year to produce roughly 630 tonnes of payable rare earth oxide. Recovery rates in the study ranged from about 88 to 89 per cent across neodymium, praseodymium and dysprosium oxides, with the company noting higher validated single-pass recovery rates of between roughly 93.5 and 97.3 per cent in test work. Iondrive chief executive Dr Grant Caffery was quoted saying the number that matters most in the study "is not the rate of return, it is the feedstock" - a reminder that the figures rest on a pre-feasibility study, not a final Investment decision, and that feedstock supply, pricing and customer agreements remain unconfirmed.

Sector Context

Australasian Metals, historically a gold and bauxite explorer in Queensland, announced on 7 September 2026 that it had secured an option over two lithium-tantalum projects in Côte d'Ivoire - the Atex and Alliance projects - held by Firering. Under the terms, Australasian Metals paid a A$100,000 fee for a three-month exclusive option to acquire up to 75 per cent of Atex and 51 per cent of Alliance, with A$1.4 million payable if the option is exercised and a further path to acquire the remaining interest for A$5 million plus a 1 per cent revenue royalty.

Risks to Consider

The company pointed to historical drilling at Atex, including intercepts of 67.97 metres at 1.23 per cent lithium oxide (including 27 metres at 2.13 per cent) and 20.77 metres at 1.65 per cent lithium oxide, with mineralisation reported over more than 800 metres of strike. Managing director Qingtao Zeng said the historical results had "delivered exceptional drill results" and that the company saw "significant upside through systematic exploration." Australasian Metals separately raised A$1 million via a Placement of shares at A$0.13 each to support its broader project portfolio, which still includes gold and bauxite Assets in Queensland.

What to Watch Next

Aruma Resources, once a Western Australian gold explorer, has repositioned around the Tillex copper-silver project in the Timmins Mining district of Ontario, Canada. Phase one diamond drilling - five holes totalling roughly 1,093 metres - combined with a downhole electromagnetic survey identified a continuous, high-strength conductive system, which the company says supports further drill targeting. A phase two programme of about 3,600 metres has since commenced.

FAQs

Q: What is the focus of the Iondrive, Australasian Metals, Aruma Resources and Neurizon Therapeutics (ASX:ION, A8G, AAJ and NUZ) update?

A:The update centres on four separate small-cap programmes and the work described in the company's latest disclosures.

Q: Does the Iondrive, Australasian Metals, Aruma Resources and Neurizon Therapeutics update establish a commercial outcome?

A:No. The information records the present stage of four separate small-cap programmes; later technical, regulatory or corporate work must be completed before its commercial position can be assessed.

Q: What uncertainties apply to four separate small-cap programmes?

A:For Iondrive, Australasian Metals, Aruma Resources and Neurizon Therapeutics, the relevant uncertainties include technical results, continuity or scale, study assumptions, approvals, funding and execution.

Q: What should readers monitor next?

A:The next points to monitor are study assumptions, option milestones, assays and clinical-trial progress.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.